Cell & Gene Therapy Manufacturing Services Global Market Report 2024

The cell & gene therapy manufacturing services market has grown rapidly in recent years. It will grow from $7.25 billion in 2023 to $8.55 billion in 2024 at a compound annual growth rate (CAGR) of 17.8%. The growth observed in the previous period can be attributed to several key factors. These include heightened investments in research and development (R&D) initiatives, supportive regulatory frameworks facilitating advancements in cell and gene therapies, a burgeoning pipeline of cell and gene therapy products, collaborations and partnerships within the industry fostering innovation, and a rising global demand for personalized medicine solutions. These factors collectively contributed to the growth witnessed in the field of cell and gene therapies during that timeframe.

The cell & gene therapy manufacturing services market is expected to see rapid growth in the next few years. It will grow to $15.77 billion in 2028 at a compound annual growth rate (CAGR) of 16.6%. The growth in the forecast period can be attributed to market maturation and commercialization, global expansion of biopharmaceutical manufacturing, increased outsourcing by pharma companies, advancements in automation and robotics, emergence of new therapeutic modalities. Major trends in the forecast period include rising demand for energy efficiency, advanced materials and technologies, compact and modular designs, electrification of transportation, focus on safety and reliability.

The cell and gene therapy manufacturing services market is anticipated to experience growth due to the increasing prevalence of diseases such as cancer. Cancer's rapid and uncontrolled cell growth has led to a surge in demand for more effective treatments, spurring the development of cell and gene therapies. For example, in January 2023, the American Cancer Society reported a 3.16% increase in cancer cases from 2021 to 2023, highlighting the escalating need for innovative therapies to address this trend.

The market for cell and gene therapy manufacturing services is expected to expand further owing to the rising adoption of personalized medicine. This approach tailors medical treatments to individual patient characteristics, significantly enhancing the efficacy of cell and gene therapies. Notably, in January 2023, the FDA's Center for Drug Evaluation and Research approved 37 new molecular entities in 2022, with 12 of them classified as personalized medicines by the Personalized Medicine Coalition (PMC), signifying the growing prominence of personalized treatments.

Technological advancements are driving trends in the cell and gene therapy manufacturing services market. Companies are embracing innovative technologies to maintain their market positions. For instance, in October 2022, Charles River Laboratories International Inc. introduced the navigation Vector Platform, simplifying GMP Adeno-Associated Virus (AAV) vector manufacturing. This platform drastically reduces the time required for viral vector gene therapy researchers compared to conventional workflows, enhancing efficiency and scalability.

Collaborations and partnerships among key players are reshaping the cell and gene therapy manufacturing services market, fostering innovation and accelerating product development. An instance is the collaboration between Allogene Therapeutics Inc. and Antion Biosciences SA to advance multiplex gene silencing for developing next-generation allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer.

In January 2021, Thermo Fisher Scientific Inc., a US-based provider of scientific instrumentation, reagents, consumables, and software services, acquired Henogen SA for $880 million in cash. The acquisition would expand Thermo Fisher's global capacity for cell and gene therapies. In the viral vector sector, it continues enhancing its capabilities for cell and gene vaccines and therapeutics globally. The laboratory products and services division of Henogens would be integrated into Thermo Fisher's Pharma Services business. Henogen SA is a Belgium-based biomanufacturing company with development and manufacturing services.

Major companies operating in the cell & gene therapy manufacturing services market report are Thermo Fisher Scientific Inc., Merck KGaA, Charles River Laboratories International Inc., Lonza Group AG, Catalent Inc., WuXi AppTec, Takara Bio Inc., Nikon Corporation, Fujifilm Holdings Corporation, F. Hoffmann-La Roche Ltd., Oxford Biomedica plc, CGT Catapult, bluebird bio Inc., Boehringer Ingelheim International GmbH, Innovative Cellular Therapeutics Co. Ltd., Samsung Biologics Co. Ltd., Novartis International AG, Pfizer Inc., Brammer Bio, AGC Biologics, Cognate BioServices Inc., Paragon Bioservices Inc., Merck KGaA operating as MilliporeSigma, Sarepta Therapeutics Inc., Spark Therapeutics Inc., Orchard Therapeutics plc, Precision BioSciences Inc., PCT a Hitachi Group Company, Aldevron LLC, BioNTech SE.

North America was the largest region in the cell and gene therapy manufacturing services market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global cell & gene therapy manufacturing services market report forecast period. The regions covered in the cell & gene therapy manufacturing services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell & gene therapy manufacturing services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of these manufacturing services include gene therapy and cell therapy. Gene therapy involves addressing underlying genetic issues to treat or prevent diseases. These services cater to both commercial manufacturing and clinical applications, targeting diverse medical indications such as central nervous system disorders, ophthalmology diseases, cardiovascular diseases, infectious diseases, orthopedic diseases, and oncology diseases. These specialized services are utilized by academic and research institutes, pharmaceutical and biotechnology companies, and other relevant entities involved in the development and production of cell and gene therapies aimed at addressing various medical conditions.

The cell and gene therapy manufacturing services market research report provides cell and gene therapy manufacturing services optical components market statistics, including cell and gene therapy manufacturing services optical components industry global market size, regional shares, competitors with a cell and gene therapy manufacturing services optical components market share, detailed cell and gene therapy manufacturing services optical components market segments, market trends and opportunities, and any further data you may need to thrive in the cell and gene therapy manufacturing services optical components industry. This cell and gene therapy manufacturing services optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cell and gene therapy manufacturing services market includes revenues earned by cell and gene therapy manufacturing and related services which include analytical and process development, current good manufacturing practice cell therapy manufacturing services of autologous and allogeneic t-cells, natural killer cells, dendritic cells, mesenchymal stem cells, hematopoietic stem cells, and more. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.